Our Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) system converges plasma membrane technology and affinity drug agents as a basis to create novel device-based therapies that are able to target the selective removal of disease-enhancing agents from the entire circulatory system. In the case of the Aethlon Hemopurifier®, we immobilize a lectin affinity agent known as "galanthus nivalis agglutinin" (GNA), which is a naturally occurring complex protein that binds to a unique high mannose structure found on...
In order to view the entire article, please read your options to the right
If you have an account with NewsRx and have purchased either a NewsRx Bundled package or a NewsRx Pass, you can log into your account below to access this article.
If you are new to NewsRx, you may also take advantage of cost-saving options such as those below to view this article.
View an unlimited number of articles for a day, week, month, etc.
Purchase a bundle of article-viewing-credits that never expire and receive a discount of up to 50%!
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.